1. Home
  2. Investing
  3. Stocks
  4. USA
  5. USOTC
  6. Alseres Pharmaceuticals Inc (CE) (ALSE)
  7. Quote

ALSE ALSE

Alseres Pharmaceuticals (CE) Stock Price

0.01
0.00 (0.0%)
0.01
Volume 0.00
Bid Price 0.01
Ask Price 0.01
News -
Day High

Low
0.01

52 Week Range

High
8.00

Day Low
Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Alseres Pharmaceuticals Inc (CE) ALSE OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.01 19:00:00
Open Price Low Price High Price Close Price Prev Close
0.01
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.01 USD

Period:

Draw Mode:

Alseres Pharmaceuticals Inc (CE) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 60.70 6.07k - $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
900.00 $ - - - -

more financials information »

Alseres Pharmaceuticals (CE) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALSE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.010.010.010.0120.000.0%
3 Months6.006.000.015.8851-5.99-99.83%
6 Months7.257.250.015.9627-7.24-99.86%
1 Year6.008.000.017.1534-5.99-99.83%
3 Years15.0015.50010.019.7915-14.99-99.93%
5 Years50.000150.00010.0125.8615-49.99-99.98%

Alseres Pharmaceuticals (CE) Description

Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS). Our lead product candidate is Altropane, a proprietary molecular imaging agent used to diagnose Parkinson's disease and dementia. Altropane is presently in Phase III clinical development for the diagnosis of Parkinson's disease. Our development strategy for Altropane anticipates entering into one or more partnerships to ensure development and commercialization of the product.


Your Recent History
USOTC
ALSE
Alseres Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.